AI, you need to think about the competition there. Molecular diagnostic space is very competitive. There's already big players occupying the space. Just to name a few, Roche, Abbott and Qiagen are already in big public/private labs in Australia. STD Screening isn't exactly an area of unmet needs. GSS has cost effective, slightly faster diagnostic panel which can definitely break into the scene but it won't exactly dominate the space. They'll take a piece of a big pie![]()
Look back in a couple of years time, it'll be either acquired at a premium or at least $1B company.
- Forums
- ASX - By Stock
- GSS
- Ann: Presenting at Bell potter healthcare conference
Ann: Presenting at Bell potter healthcare conference, page-10
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GSS (ASX) to my watchlist
|
|||||
Last
80.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $181.2M |
Open | High | Low | Value | Volume |
79.0¢ | 80.0¢ | 77.0¢ | $307.5K | 390.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 78.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
80.0¢ | 296 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 0.780 |
1 | 12500 | 0.750 |
1 | 1000 | 0.740 |
3 | 16361 | 0.735 |
3 | 102069 | 0.730 |
Price($) | Vol. | No. |
---|---|---|
0.800 | 296 | 1 |
0.820 | 8456 | 3 |
0.845 | 1184 | 1 |
0.850 | 23008 | 1 |
0.860 | 12935 | 1 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
GSS (ASX) Chart |